Threshold Pharmaceuticals Initiates 440-Patient,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 1, 2014) - Threshold Pharmaceuticals, Inc. ( NASDAQ : THLD ) today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in advanced non-squamous non-small cell lung cancer (NSCLC). The international Phase 2 trial is designed to compare the combination of TH-302 and pemetrexed versus the combination of pemetrexed and placebo as second-line therapy in this patient population. A TH-302 dose of 400 mg/m 2 will be utilized in combination with full-dose pemetrexed. Overall survival is the primary endpoint; secondary endpoints include safety and assessment of anti-tumor activity as determined by progression-free survival and objective response rate.

"The initiation of this trial is yet another example of our commitment, and that of our partner Merck KGaA based in Darmstadt, Germany, to develop TH-302 for the potential treatment of a broad range of cancers," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "Independent studies have demonstrated the presence of hypoxia in tumors from patients with NSCLC. 1 Early clinical research conducted by Threshold also supports further evaluation of TH-302 in combination with pemetrexed as a potential second-line treatment for patients with non-squamous NSCLC, many of whom still face a poor prognosis because of limited treatment options."

"While over the past decade the ability to detect and treat specific mutations in NSCLC has proven beneficial to some patients with recurrent disease who harbor those mutations, there is still a significant need for the development of new safe and effective medicines that improve survival outcomes," said Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, UCLA Hematology & Oncology, and principal investigator of the ongoing trial. "TH-302 is a hypoxia-activated prodrug that has shown encouraging anti-tumor activity across a wide range of cancers in investigational trials, and we are excited about evaluating TH-302 in combination with pemetrexed as potential second-line treatment for patients with non-squamous NSCLC."

In a completed Phase 1/2 study that evaluated TH-302 in combination with full-dose pemetrexed in 18 patients with relapsed/refractory non-squamous NSCLC, median progression-free survival was 7.0 months and median overall survival was 14.9 months. Of 15 patients evaluable for response, 6 (40%) achieved a partial response including 4 confirmed responses, 6 (40%) achieved stable disease, and 3 (20%) had progressive disease. The most common adverse events following combination therapy of TH-302 and pemetrexed were fatigue, anemia, stomatitis and nausea.

About NSCLC Lung cancer is the leading cause of cancer death worldwide claiming the lives of some 1.4 million people each year. 2 There are approximately 1.6 million new cases of lung cancer diagnosed each year. 2 About 85% of lung cancers are non-small cell lung cancer (NSCLC), and 15% are small-cell lung cancers (SCLC). 3 There are several types of NSCLC, each characterized by different types of cancer cells that grow and spread in unique ways. The two main subdivisions are "squamous" or "non-squamous", with non-squamous comprising 70-75%. 3 The American Society for Clinical Oncology (ASCO) guidelines recommend that first-line treatment for NSCLC should include a platinum-containing regimen in combination with a second therapeutic agent. 4 In the second-line setting, chemotherapy is continued until disease progression or unacceptable toxicity. 4 Historically, non-squamous NSCLC patients receiving second-line chemotherapy show median progression-free survival of approximately 3 to 4 months and median overall survival of approximately 8 to 10 months.

About TH-302 TH-302 is an investigational hypoxia-activated prodrug that is designed to be activated under tumor hypoxic conditions, a hallmark of many cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood supply as a result of aberrant vasculature. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma, and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer (MAESTRO). Both Phase 3 trials are being conducted under Special Protocol Agreements with the U.S. Food and Drug Administration (FDA). The FDA and the European Commission have granted TH-302 Orphan Drug Designations for the treatment of soft tissue sarcoma and pancreatic cancer. TH-302 is also being investigated in earlier-stage clinical trials of other solid tumors and hematological malignancies, in combination with chemotherapy and antiangiogenic therapy, and for certain cancers, is being investigated as a monotherapy.

Threshold has a global license and co-development agreement for TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.

About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ( www.thresholdpharm.com ).

Forward-Looking Statements Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of TH-302, statements regarding the TH-302 clinical development program, including the expected enrollment and conduct of ongoing clinical trials including the above-described Phase 2 clinical trial, and statements regarding continued collaborative activities under Threshold's collaboration with Merck KGaA, Darmstadt, Germany. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: the ability of Threshold and Merck KGaA, Darmstadt, Germany, to enroll or complete TH-302 clinical trials; the time and expense required to conduct such clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results); the risk that later trials may not confirm the results of earlier trials; Threshold's and Merck KGaA's dependence on single source suppliers, including the risk that these single source suppliers may be unable to meet clinical supply demands for TH-302 which could significantly delay the development of TH-302; risks related to Threshold's dependence on its collaborative relationship with Merck KGaA, Darmstadt, Germany, including its dependence on decisions by Merck KGaA, Darmstadt, Germany, regarding the amount and timing of resource expenditures for the development of TH-302; and Threshold's need for and the availability of resources to develop TH-302 and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on May 1, 2014 and is available from the SEC's website ( www.sec.gov ) and on our website ( www.thresholdpharm.com ) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

References

1. Zegers, CML et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. Radiotherapy and Oncology 2013;109:58-64.

2. American Cancer Society. Global Cancer Facts & Figures (2 nd edition). http://www.cancer.org/acs/groups/content/@epi...027766.pdf . Accessed June 30, 2014.

3. American Cancer Society. Lung Cancer (Non-Small Cell). http://www.cancer.org/acs/groups/cid/document...15-pdf.pdf . Accessed June 30, 2014.

4. Azzoli, CG et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2009;27:6251-6266.

Contact Laura Hansen, Ph.D. Senior Director, Corporate Communications Phone: 650-474-8206 E-mail: lhansen@thresholdpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 87

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 122

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 117

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 9

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 84

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 22

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 72

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 36

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Online Auction of Distinctive Ranch Properties

Updated Category News Views 373

Exciting Online Auction of Distinctive Ranch Properties SVN Auction Services, LLC and SVN | Walt Arnold Commercial Brokerage are thrilled to announce an exciting online auction featuring a unique ranch retreat. Set on 52 acres, this estate boasts a spacious 4,400 square foot main home along with seven handcrafted log and stone cabins. This is a rare chance to acquire a...

Continue Reading
Teladoc Health Unveils Innovative Wellbound EAP Initiative

Updated Category News Views 461

Introduction to Teladoc Health's Wellbound EAP Discover how Teladoc Health, a leader in virtual healthcare, is revolutionizing employee wellness with the launch of Wellbound, a new Employee Assistance Program (EAP). This innovative initiative is designed to enhance employee engagement and support workforce health across various sectors. A Comprehensive Approach to...

Continue Reading
Mirion Technologies Achieves New Heights with Stock Surge

Updated Category News Views 121

Mirion Technologies Reaches a Milestone Stock High Mirion Technologies Inc. (NYSE: MIR) has made headlines recently, achieving a remarkable new 52-week high of $14.81. This significant achievement underscores the company's strong performance, with an impressive year-over-year stock value increase of over 113%. Investors are expressing heightened confidence in Mirion’s...

Continue Reading
Understanding Short Interest and Market Sentiment for BCH

Updated Category News Views 127

Short Interest Trends for Banco De Chile Banco De Chile's short percent of float has recently increased by 5.0% since the last report. Currently, there are approximately 519 thousand shares sold short, representing 0.21% of all available trading shares. Given the current trading volume, it would take traders about 2.09 days to cover their short positions on average....

Continue Reading
Pixalate Insights Reveal Top Brazilian Publishers for Ads

Updated Category News Views 170

Celebrating Quality in Programmatic Advertising As the digital landscape evolves, ensuring quality in programmatic advertising is more crucial than ever. In January 2025, Pixalate, a global leader in ad fraud prevention and compliance analytics, released its much-anticipated Publisher Trust Index (PTI) for Brazil. This index sheds light on the top publishers and apps...

Continue Reading